Expand ALT Menu
ALT MENU

ALT Latest Press Releases

-- December 2, 2024 --

Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders Globe Newswire 7:30 AM

-- November 26, 2024 --

Altimmune to Participate at Two Upcoming Investor Conferences Globe Newswire 7:30 AM

-- November 15, 2024 --

Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting 2024 Globe Newswire 11:00 AM

-- November 12, 2024 --

Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update Globe Newswire 7:00 AM

-- November 11, 2024 --

Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:30 AM
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer Globe Newswire 7:30 AM

-- November 7, 2024 --

Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity Globe Newswire 7:30 AM

-- November 6, 2024 --

Altimmune to Participate at Two Upcoming Investor Conferences Globe Newswire 7:30 AM

-- November 4, 2024 --

Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 Globe Newswire 7:30 AM

-- October 15, 2024 --

Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting 2024 Globe Newswire 8:00 AM

-- October 1, 2024 --

Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference Globe Newswire 7:30 AM

-- September 30, 2024 --

Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Globe Newswire 7:30 AM

-- September 10, 2024 --

Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes Globe Newswire 7:45 AM

-- September 5, 2024 --

Sprout Social, Altimmune, Equinix, and Globe Life Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information Globe Newswire 12:00 PM

-- September 3, 2024 --

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes Globe Newswire 7:30 AM

-- August 8, 2024 --

Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update Globe Newswire 7:00 AM

-- August 1, 2024 --

Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 Globe Newswire 7:30 AM

-- July 30, 2024 --

ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm Globe Newswire 9:00 PM

-- July 25, 2024 --

Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology Globe Newswire 7:30 AM

-- July 22, 2024 --

Sprout Social, Altimmune, Equinix, and Globe Life Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information Globe Newswire 10:24 AM